The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer “Omics”
暂无分享,去创建一个
Ioana Berindan-Neagoe | Diana Gulei | Lavinia L. Pruteanu | Cornelia Braicu | I. Berindan‐Neagoe | C. Braicu | C. Iuga | Mihail Buse | Diana Gulei | Cristina Alexandra Ciocan-Cartita | Ancuța Jurj | Mihail Buse | Lajos Raduly | Roxana Cojocneanu | Lavinia Lorena Pruteanu | Cristina Adela Iuga | Ovidiu Coza | R. Cojocneanu | O. Coza | Cristina Alexandra Ciocan-Cȃrtiţă | Lajos Raduly | A. Jurj | L. Pruteanu | L. Raduly
[1] G. Calin,et al. Noncoding RNAs in Lung Cancer Angiogenesis , 2017 .
[2] D. Hochstrasser,et al. Evaluation and identification of dioxin exposure biomarkers in human urine by high-resolution metabolomics, multivariate analysis and in vitro synthesis. , 2016, Toxicology letters.
[3] Z. Kokot,et al. Mass spectrometry as a tool for biomarkers searching in gynecological oncology. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] S. Hanash,et al. Application of proteomics to cancer early detection. , 2011, Cancer journal.
[5] Oliver M. Bernhardt,et al. Optimization of Experimental Parameters in Data-Independent Mass Spectrometry Significantly Increases Depth and Reproducibility of Results* , 2017, Molecular & Cellular Proteomics.
[6] L. Kowalski,et al. Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches , 2012, Front. Pharmacol..
[7] Ishtiaq Rehman,et al. The Use of Proteomics in Urological Research , 2005 .
[8] I. Lossos,et al. MiR-181 family-specific behavior in different cancers: a meta-analysis view , 2018, Cancer and Metastasis Reviews.
[9] H. Schiebel,et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. , 1996, Clinical chemistry.
[10] Qin Fu,et al. Preparation of proteins and peptides for mass spectrometry analysis in a bottom-up proteomics workflow. , 2009, Current protocols in molecular biology.
[11] J. Solassol,et al. Autoantibody signatures: progress and perspectives for early cancer detection , 2011, Journal of cellular and molecular medicine.
[12] Z. Kokot,et al. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer , 2017, BMC Cancer.
[13] H. Pass,et al. Autoantibodies against tumor-associated antigens in the early detection of lung cancer. , 2016, Lung cancer.
[14] J. Foekens,et al. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations , 2013, Oncotarget.
[15] K. Makambi,et al. Quantitative Liquid Chromatography-Mass Spectrometry-Multiple Reaction Monitoring (LC-MS-MRM) Analysis of Site-specific Glycoforms of Haptoglobin in Liver Disease* , 2013, Molecular & Cellular Proteomics.
[16] P. Hoffmann,et al. Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery , 2011, International journal of molecular sciences.
[17] J. Werner,et al. Immunotherapy as an Option for Cancer Treatment , 2017, Archivum Immunologiae et Therapiae Experimentalis.
[18] E. Thiel,et al. High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma. , 2007, Neuro-oncology.
[19] J. Henion,et al. Peer Reviewed: Sample Preparation for LC/MS/MS: Analyzing Biological and Environmental Samples , 1998 .
[20] E. Calvo,et al. Proteomics: New insights into rheumatic diseases , 2009, Proteomics. Clinical applications.
[21] M. Verma. Personalized Medicine and Cancer , 2012, Journal of personalized medicine.
[22] S. Hanash,et al. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. , 2016, Molecular cell.
[23] A. Walch,et al. In Situ Metabolomics in Cancer by Mass Spectrometry Imaging , 2017, Advances in cancer research.
[24] S. Fischer,et al. Changes in Cancer Cell Metabolism Revealed by Direct Sample Analysis with MALDI Mass Spectrometry , 2013, PloS one.
[25] Surinder Kaur,et al. Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics , 2014, The AAPS Journal.
[26] C. Proud,et al. mTOR inhibitors in cancer therapy , 2016, F1000Research.
[27] S. Giridharan,et al. Is it safe for pregnant health-care professionals to handle cytotoxic drugs? A review of the literature and recommendations , 2014, Ecancermedicalscience.
[28] P. Tchounwou,et al. Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.
[29] Brendan Prideaux,et al. Mass spectrometry imaging for drug distribution studies. , 2012, Journal of proteomics.
[30] J. Bell. Predicting disease using genomics , 2004, Nature.
[31] Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging , 2016, Clinical and Translational Medicine.
[32] Ruedi Aebersold,et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer , 2011, Proceedings of the National Academy of Sciences.
[33] I. Berindan‐Neagoe,et al. Zearalenone Mycotoxin Affects Immune Mediators, MAPK Signalling Molecules, Nuclear Receptors and Genome-Wide Gene Expression in Pig Spleen , 2015, PloS one.
[34] T. Migone,et al. A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies , 2015, Blood Cancer Journal.
[35] S. Marx,et al. Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1* , 2010, The Journal of Biological Chemistry.
[36] Junfu Wei,et al. An Optimized High Throughput Clean-Up Method Using Mixed-Mode SPE Plate for the Analysis of Free Arachidonic Acid in Plasma by LC-MS/MS , 2015, International journal of analytical chemistry.
[37] G. Calin,et al. Molecular Pathways Molecular Pathways : microRNAs , Cancer Cells , and Microenvironment , 2014 .
[38] Robert W Johnson,et al. Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist. , 2019, ACS medicinal chemistry letters.
[39] S. Mathivanan,et al. Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy , 2017, Proteomics.
[40] H. Ressom,et al. Metabolomic profiling of breast tumors using ductal fluid , 2016, International journal of oncology.
[41] I. Berindan‐Neagoe,et al. Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? , 2013, Breast.
[42] Chuanhao Tang,et al. Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma , 2017, PloS one.
[43] G. Akpinar,et al. Proteomics Analysis of Tissue Samples Reveals Changes in Mitochondrial Protein Levels in Parathyroid Hyperplasia over Adenoma. , 2017, Cancer genomics & proteomics.
[44] R. Ahmed,et al. mTOR Promotes Antiviral Humoral Immunity by Differentially Regulating CD4 Helper T Cell and B Cell Responses , 2016, Journal of Virology.
[45] U. Sack,et al. New Platform Technology for Comprehensive Serological Diagnostics of Autoimmune Diseases , 2012, Clinical & developmental immunology.
[46] J. Yates,et al. Protein analysis by shotgun/bottom-up proteomics. , 2013, Chemical reviews.
[47] Ara Darzi,et al. Chemo-informatic strategy for imaging mass spectrometry-based hyperspectral profiling of lipid signatures in colorectal cancer , 2014, Proceedings of the National Academy of Sciences.
[48] E. Diamandis,et al. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.
[49] Sanjeeva Srivastava,et al. Proteomic databases and tools to decipher post-translational modifications. , 2011, Journal of proteomics.
[50] R. Chiodini,et al. The impact of next-generation sequencing on genomics. , 2011, Journal of genetics and genomics = Yi chuan xue bao.
[51] A. Tessitore,et al. Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors , 2013, International journal of proteomics.
[52] J. Vermorken,et al. Advances in the systemic treatment of head and neck cancers , 2010, Current opinion in oncology.
[53] Y. Liu,et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease , 2015, Journal of ginseng research.
[54] H. Fujimoto,et al. Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer , 2018, Case Reports in Oncology.
[55] D. Harvey,et al. Characterization of oligosaccharide composition and structure by quadrupole ion trap mass spectrometry. , 1997, Rapid communications in mass spectrometry : RCM.
[56] Ruth Etzioni,et al. Early detection: The case for early detection , 2003, Nature Reviews Cancer.
[57] Jianxin Gu,et al. Discovery of Non-invasive Glycan Biomarkers for Detection and Surveillance of Gastric Cancer , 2017, Journal of Cancer.
[58] B. Meiser,et al. Quantification of Sirolimus by Liquid Chromatography-Tandem Mass Spectrometry Using On-Line Solid-Phase Extraction , 2002, Clinical chemistry and laboratory medicine.
[59] I. Berindan‐Neagoe,et al. TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: a pilot study. , 2014, Journal of gastrointestinal and liver diseases : JGLD.
[60] A. Emili,et al. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics , 2006, Nature Protocols.
[61] Xuan-xian Peng,et al. Functional metabolomics: from biomarker discovery to metabolome reprogramming , 2015, Protein & Cell.
[62] Tony Gutschner,et al. The Dark Side of the Epitranscriptome: Chemical Modifications in Long Non-Coding RNAs , 2017, International journal of molecular sciences.
[63] R. Jain,et al. Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[64] Á. Végvári. Drug localizations in tissue by mass spectrometry imaging. , 2015, Biomarkers in medicine.
[65] Dietrich A. Volmer,et al. Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC-MS/MS. , 2014, The Analyst.
[66] François-Michel Boisvert,et al. Proteomics methods for subcellular proteome analysis , 2013, The FEBS journal.
[67] Bryan P. Early,et al. A Protease for Middle Down Proteomics , 2012, Nature Methods.
[68] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[69] Zuofeng Li,et al. A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis , 2016, Oncotarget.
[70] Antonio Federico,et al. Transcriptome Profiling in Human Diseases: New Advances and Perspectives , 2017, International journal of molecular sciences.
[71] R. Rosell,et al. The combination of checkpoint immunotherapy and targeted therapy in cancer. , 2017, Annals of translational medicine.
[72] Jessica R Gooding,et al. Metabolomics applied to the pancreatic islet. , 2016, Archives of biochemistry and biophysics.
[73] Bih-Rong Wei,et al. Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. , 2014, Biomarkers in medicine.
[74] F. Vogenberg,et al. Personalized medicine: part 1: evolution and development into theranostics. , 2010, P & T : a peer-reviewed journal for formulary management.
[75] B. Kaplan,et al. Strategies for the management of adverse events associated with mTOR inhibitors. , 2014, Transplantation reviews.
[76] P. V. Van Schil,et al. Surgical Management of Stage IIIA Non-Small Cell Lung Cancer , 2017, Front. Oncol..
[77] H. Mischak,et al. Mass spectrometry based proteomics in urine biomarker discovery , 2007, World Journal of Urology.
[78] T. Veenstra,et al. Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue , 2014, PloS one.
[79] F Baganz,et al. Systematic functional analysis of the yeast genome. , 1998, Trends in biotechnology.
[80] I. Fournier,et al. On-tissue protein identification and imaging by MALDI-Ion mobility mass spectrometry , 2010, Journal of the American Society for Mass Spectrometry.
[81] Orli G. Bahcall. Precision medicine , 2015, Nature.
[82] Hyunsu Ju,et al. Biomarker Discovery for Early Detection of Hepatocellular Carcinoma in Hepatitis C–infected Patients* , 2013, Molecular & Cellular Proteomics.
[83] N. Manicke,et al. Targeted Protein Detection Using an All-in-One Mass Spectrometry Cartridge. , 2017, Journal of the American Chemical Society.
[84] P. Ramírez,et al. Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation. , 2016, World journal of transplantation.
[85] N. Barbarroja,et al. Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases , 2008, Lupus.
[86] T. Dassopoulos,et al. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease , 2018, Current Gastroenterology Reports.
[87] R. Casadonte,et al. MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review). , 2015, International journal of oncology.
[88] S. Cai,et al. Hyperplex-MRM: a hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker. , 2013, Journal of proteome research.
[89] D. Characiejus,et al. Prediction of response in cancer immunotherapy. , 2011, Anticancer research.
[90] O. Dada,et al. High-Resolution Capillary Zone Electrophoresis with Mass Spectrometry Peptide Mapping of Therapeutic Proteins: Peptide Recovery and Post-translational Modification Analysis in Monoclonal Antibodies and Antibody-Drug Conjugates. , 2017, Analytical chemistry.
[91] R. Gomis,et al. Proteomics in obesity research , 2009, Proteomics. Clinical applications.
[92] X. Wang,et al. Metabolic Profiles are Principally Different between Cancers of the Liver, Pancreas and Breast , 2014, International journal of biological sciences.
[93] Janne Lehtiö,et al. Mass spectrometry-based plasma proteomics: state of the art and future outlook , 2014, Expert review of proteomics.
[94] Denis C. Bauer,et al. A Comparative Study of Techniques for Differential Expression Analysis on RNA-Seq Data , 2014, bioRxiv.
[95] Stefani N. Thomas,et al. Advances in mass spectrometry-based clinical biomarker discovery , 2016, Clinical Proteomics.
[96] Ya Zhang,et al. Progress in the chemotherapeutic treatment of osteosarcoma. , 2018, Oncology letters.
[97] T. Mauriala,et al. Mass spectrometric tools for cell and tissue studies. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[98] G. Deng,et al. Applications of mass spectrometry in early stages of target based drug discovery. , 2006, Journal of pharmaceutical and biomedical analysis.
[99] David A Bennett,et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. , 2005, Clinical chemistry.
[100] P. Forget,et al. A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research , 2017, Front. Oncol..
[101] P. Hoffmann,et al. Proteomics of endometrial cancer diagnosis, treatment, and prognosis , 2016, Proteomics. Clinical applications.
[102] P. Schellhammer,et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.
[103] A. Glas,et al. Implementation of a novel microarray‐based diagnostic test for cancer of unknown primary , 2009, International journal of cancer.
[104] R. Jain. Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.
[105] Paolo Vineis,et al. The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability , 2009, Environmental health : a global access science source.
[106] Cornelia M van Duijn,et al. Genome-based prediction of common diseases: advances and prospects. , 2008, Human molecular genetics.
[107] J. Henion,et al. Sample preparation for LC/MS/MS: analyzing biological and environmental samples. , 1998, Analytical chemistry.
[108] S. Hanash,et al. Mass spectrometry based proteomics for absolute quantification of proteins from tumor cells. , 2015, Methods.
[109] U. Völker,et al. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma , 2014, Proteomics.
[110] O. Shpigun,et al. A validated LC-MS/MS method for rapid determination of methotrexate in human saliva and its application to an excretion evaluation study. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[111] Hyewon Seo,et al. A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study. , 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[112] R. Sallam. Proteomics in Cancer Biomarkers Discovery: Challenges and Applications , 2015, Disease markers.
[113] C. S. Allardyce,et al. Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin. , 2002, Rapid communications in mass spectrometry : RCM.
[114] Jeroen A. A. Demmers,et al. Improvement of ubiquitylation site detection by Orbitrap mass spectrometry. , 2018, Journal of proteomics.
[115] Nicola Bizzaro,et al. Current state of diagnostic technologies in the autoimmunology laboratory , 2012, Clinical chemistry and laboratory medicine.
[116] T. Luider,et al. Collagen Peptides in Urine: A New Promising Biomarker for the Detection of Colorectal Liver Metastases , 2013, PloS one.
[117] I. Berindan‐Neagoe,et al. The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression , 2018, Cell Death & Disease.
[118] Chibo Liu,et al. The Application of SELDI-TOF-MS in Clinical Diagnosis of Cancers , 2011, Journal of biomedicine & biotechnology.
[119] K. Al-Anazi,et al. Methotrexate-Induced Acute Leukemia: Report of Three Cases and Review of the Literature , 2009, Clinical medicine. Case reports.
[120] H. Lilja,et al. Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring* , 2013, Molecular & Cellular Proteomics.
[121] G. Kristiansen,et al. Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS , 2015, BioMed research international.
[122] K. Geoghegan,et al. Biochemical applications of mass spectrometry in pharmaceutical drug discovery. , 2005, Mass spectrometry reviews.
[123] Rui Chen,et al. Promise of personalized omics to precision medicine , 2013, Wiley interdisciplinary reviews. Systems biology and medicine.
[124] M. Vogeser,et al. Liquid Chromatography Tandem-mass Spectrometry (LC-MS/MS) - Technique and Applications in Endocrinology , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[125] David Baltimore,et al. Our genome unveiled , 2001, Nature.
[126] Jianhua Zheng,et al. Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model , 2017, BMC Genomics.
[127] R. Burlacu,et al. Exposure to zearalenone mycotoxin alters in vitro porcine intestinal epithelial cells by differential gene expression. , 2015, Toxicology letters.
[128] I. Berindan‐Neagoe,et al. Evaluation of cellular and molecular impact of zearalenone and Escherichia coli co-exposure on IPEC-1 cells using microarray technology , 2016, BMC Genomics.
[129] H. Olsson,et al. Analysis of Alpha-Synuclein in Malignant Melanoma – Development of a SRM Quantification Assay , 2014, PloS one.
[130] M. Mann,et al. Proteomic analysis of post-translational modifications , 2003, Nature Biotechnology.
[131] He Ren,et al. Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis , 2016, Molecular oncology.
[132] David J Hunter,et al. Genomics and proteomics in epidemiology: treasure trove or "high-tech stamp collecting"? , 2006, Epidemiology.
[133] A. Whetton,et al. How will haematologists use proteomics? , 2007, Blood reviews.
[134] M. Ferrari,et al. Clinical proteomics: Written in blood , 2003, Nature.
[135] J. von Hagen,et al. Isolation of subcellular organelles and structures. , 2009, Methods in enzymology.
[136] I. Duarte,et al. Insights into the impact of silver nanoparticles on human keratinocytes metabolism through NMR metabolomics. , 2016, Archives of biochemistry and biophysics.
[137] D. Swinkels,et al. Immunoproteomics: From biomarker discovery to diagnostic applications , 2008, Proteomics. Clinical applications.
[138] Ioana Berindan-Neagoe,et al. The new era of nanotechnology, an alternative to change cancer treatment , 2017, Drug design, development and therapy.
[139] C. Stewart,et al. Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[140] G A Nagana Gowda,et al. Overview of mass spectrometry-based metabolomics: opportunities and challenges. , 2014, Methods in molecular biology.
[141] Moyez Dharsee,et al. Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival , 2012, PloS one.
[142] Donald Kennedy,et al. Breakthrough of the Year , 2007, Science.
[143] M. Ali,et al. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy , 2015, International Journal of Gynecologic Cancer.
[144] Ioana Berindan-Neagoe,et al. Exosomes-Small Players, Big Sound. , 2018, Bioconjugate chemistry.
[145] Youxin Wang,et al. Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts , 2017, Oncotarget.
[146] D. Chan,et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.
[147] A. Bracher,et al. Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin , 2013, Molecular and Cellular Biology.
[148] L. Huber,et al. Organelle Proteomics Implications for Subcellular Fractionation in Proteomics , 2003 .
[149] G. Hortin. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. , 2006, Clinical chemistry.
[150] D. Kell,et al. Metabolomics by numbers: acquiring and understanding global metabolite data. , 2004, Trends in biotechnology.
[151] T. Veenstra,et al. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry , 2004, Proteomics.
[152] L. Kenny,et al. ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics , 2011 .
[153] R. Spizzo,et al. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis , 2015, Gut.
[154] G. Calin,et al. MicroRNAome genome: A treasure for cancer diagnosis and therapy , 2014, CA: a cancer journal for clinicians.
[155] P. Schellhammer,et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.
[156] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[157] Y. Duan,et al. The early diagnosis and monitoring of squamous cell carcinoma via saliva metabolomics , 2014, Scientific Reports.
[158] David Fenyö,et al. Protein quantitation using mass spectrometry. , 2010, Methods in molecular biology.
[159] L. Gesualdo,et al. Management of Side Effects of Sirolimus Therapy , 2009, Transplantation.
[160] J. Kim,et al. Targeted Mass Spectrometric Approach for Biomarker Discovery and Validation with Nonglycosylated Tryptic Peptides from N-linked Glycoproteins in Human Plasma* , 2011, Molecular & Cellular Proteomics.
[161] B. Tian,et al. RNA‐Seq methods for transcriptome analysis , 2017, Wiley interdisciplinary reviews. RNA.
[162] G. Theodoridis,et al. Studying the effect of storage conditions on the metabolite content of red wine using HILIC LC-MS based metabolomics. , 2016, Food chemistry.
[163] M. R. Groseclose,et al. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. , 2011, Bioanalysis.
[164] S. Kanekal,et al. Cyclophosphamide Toxicity , 1991, Drugs.
[165] B. Döme,et al. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. , 2011, Journal of proteomics.
[166] I. Berindan‐Neagoe,et al. Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets , 2017, International journal of molecular sciences.
[167] Richard Z. Liu,et al. Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. , 2010, Journal of proteome research.
[168] Emma L. Schymanski,et al. Small Molecule Identification with MOLGEN and Mass Spectrometry , 2013, Metabolites.
[169] Leigh Anderson,et al. Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.
[170] Isaiah Norton,et al. Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis , 2014, Proceedings of the National Academy of Sciences.
[171] A. Jarmusch,et al. Direct drug analysis from oral fluid using medical swab touch spray mass spectrometry. , 2015, Analytica chimica acta.
[172] A. Paradiso,et al. Genetic alterations in sporadic triple negative breast cancer. , 2018, Breast.
[173] G. Calin,et al. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? , 2014, Cell Death and Differentiation.
[174] Sven Diederichs,et al. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non‐coding RNA and synonymous mutations , 2016, EMBO molecular medicine.
[175] Christodoulos A. Floudas,et al. Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database , 2011, Scientific reports.
[176] F. Slack,et al. Junk DNA and the long non-coding RNA twist in cancer genetics , 2015, Oncogene.
[177] X. Zheng,et al. FKBP12-Rapamycin-associated Protein or Mammalian Target of Rapamycin (FRAP/mTOR) Localization in the Endoplasmic Reticulum and the Golgi Apparatus* , 2004, Journal of Biological Chemistry.
[178] C. Ho,et al. Electrospray ionisation mass spectrometry: principles and clinical applications. , 2003, The Clinical biochemist. Reviews.
[179] G. Calin,et al. MicroRNAs and cancer therapy - from bystanders to major players. , 2013, Current medicinal chemistry.
[180] J. Ko,et al. Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry. , 2014, Journal of proteomics.
[181] E. Wang,et al. A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. , 2013, Journal of proteomics.
[182] A. Walch,et al. MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice , 2015, Laboratory Investigation.
[183] M. Molloy,et al. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours , 2015, BMC Cancer.
[184] I. Berindan‐Neagoe,et al. Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics , 2015, Acta odontologica Scandinavica.
[185] James G. Bollinger,et al. A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva , 2016, Proteomics.
[186] N. Kelleher,et al. Top Down proteomics: facts and perspectives. , 2014, Biochemical and biophysical research communications.
[187] H. Tojo,et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.
[188] A. Baccarelli,et al. Global DNA Hypomethylation Is Associated with High Serum-Persistent Organic Pollutants in Greenlandic Inuit , 2008, Environmental health perspectives.
[189] Bruno Domon,et al. Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples , 2016, Oncotarget.
[190] F. Blanco,et al. Proteomic characterization of human normal articular chondrocytes: A novel tool for the study of osteoarthritis and other rheumatic diseases , 2005, Proteomics.
[191] Robert Verpoorte,et al. Extraction for metabolomics: access to the metabolome. , 2014, Phytochemical analysis : PCA.
[192] F. M. Huennekens,et al. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. , 1994, Advances in enzyme regulation.